XML 92 R40.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Collaboration Agreements - Additional Information (Detail) |  |  | 1 Months Ended | 3 Months Ended | 12 Months Ended | 32 Months Ended
--- | --- | --- | --- | --- | --- | ---
Apr. 02, 2018 | May 05, 2016 USD ($) $ / shares shares | Apr. 30, 2018 USD ($) Target $ / shares shares | Feb. 28, 2018 USD ($) | May 31, 2016 USD ($) Program $ / shares shares | Dec. 31, 2018 USD ($) | Sep. 30, 2018 USD ($) | Jun. 30, 2018 USD ($) | Mar. 31, 2018 USD ($) | Dec. 31, 2017 USD ($) | Sep. 30, 2017 USD ($) | Jun. 30, 2017 USD ($) | Mar. 31, 2017 USD ($) | Dec. 31, 2018 USD ($) | Dec. 31, 2017 USD ($) | Dec. 31, 2016 USD ($) | Dec. 31, 2018 USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity investment aggregate purchase price |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 60,000,000 | $ 93,509,000 | $ 30,000,000 |
Collaboration and license agreement, deferred revenue current |  |  |  |  |  | $ 100,945,000 |  |  |  | $ 1,275,000 |  |  |  | 100,945,000 | 1,275,000 |  | $ 100,945,000
Proceeds from issuance of ordinary shares, net of offering costs |  |  |  |  |  |  |  |  |  |  |  |  |  | 60,000,000 | 93,509,000 | 30,000,000 |
Collaboration revenue recognized |  |  |  |  |  | 3,620,000 | $ 4,493,000 | $ 4,879,000 | $ 1,422,000 | $ 1,098,000 | $ 1,315,000 | $ 1,097,000 | $ 383,000 | $ 14,414,000 | 3,893,000 | 1,092,000 |
Pfizer Inc. [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of research programs, counterparty nomination | Program |  |  |  |  | 5 |  |  |  |  |  |  |  |  |  |  |  |
Research term, description |  |  |  |  |  |  |  |  |  |  |  |  |  | Under the Pfizer Collaboration Agreement, the parties agreed to collaborate during a four-year research term. During the research term, the Company is responsible to use its commercially reasonable efforts to advance up to five programs through to the selection of clinical candidates. At that stage, Pfizer may elect to license any of these Pfizer Programs exclusively and obtain exclusive rights to undertake the clinical development of the resulting clinical candidates into products and the potential commercialization of any such products thereafter. |  |  |
Collaboration agreement, additional period after research program |  | 2 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Up-front consideration received |  | $ 10,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 4,900,000 | $ 3,900,000 | $ 1,100,000 | 9,900,000
Collaboration and license agreement, deferred revenue |  |  |  |  |  | 8,700,000 |  |  |  |  |  |  |  | 8,700,000 |  |  | 8,700,000
Collaboration and license agreement, deferred revenue current |  |  |  |  |  | 6,800,000 |  |  |  |  |  |  |  | $ 6,800,000 |  |  | 6,800,000
Remaining research term |  |  |  |  |  |  |  |  |  |  |  |  |  | 16 months |  |  |
Takeda [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Up-front consideration received |  |  | $ 110,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research, License and Option Agreement [Member] | Pfizer Inc. [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment under collaboration agreement |  |  |  |  | $ 10,000,000 |  |  |  |  |  |  |  |  |  |  |  |
Collaboration agreement refundable |  |  |  |  | $ 0 |  |  |  |  |  |  |  |  |  |  |  |
Shares issued under equity agreement | shares |  | 1,875,000 |  |  | 1,875,000 |  |  |  |  |  |  |  |  |  |  |  |
Equity investment aggregate purchase price |  | $ 30,000,000 |  |  | $ 30,000,000 |  |  |  |  |  |  |  |  |  |  |  |
Purchase price per share | $ / shares |  | $ 16.00 |  |  | $ 16.00 |  |  |  |  |  |  |  |  |  |  |  |
Collaborative agreement research term |  |  |  |  | 4 years |  |  |  |  |  |  |  |  |  |  |  |
Collaboration agreement termination period |  | 90 days |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration And License Agreement [Member] | Category One Programs [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of global costs and potential profits sharing ratio |  |  | 50.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration And License Agreement [Member] | Takeda [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment under collaboration agreement |  |  | $ 110,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration agreement termination period | 180 days |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration and license agreement, deferred revenue |  |  |  |  |  | 160,400,000 |  |  |  |  |  |  |  | $ 160,400,000 |  |  | 160,400,000
Collaboration and license agreement, deferred revenue current |  |  |  |  |  | 94,100,000 |  |  |  |  |  |  |  | 94,100,000 |  |  | 94,100,000
Collaboration and license agreement month and year |  |  | 2018-02 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fund receivable for research and preclinical activities |  |  | $ 60,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research term under collaboration and license agreement |  |  | 4 years |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration agreement commencement date | Apr. 02, 2018 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration revenue recognized |  |  |  |  |  |  |  |  |  |  |  |  |  | 9,600,000 |  |  |
Collaboration and license agreement, accounts receivable |  |  |  |  |  | 60,000,000 |  |  |  |  |  |  |  | 60,000,000 |  |  | 60,000,000
Collaboration and license agreement, accounts receivable current |  |  |  |  |  | $ 10,000,000 |  |  |  |  |  |  |  | $ 10,000,000 |  |  | $ 10,000,000
Collaboration And License Agreement [Member] | Takeda [Member] | Category One Programs [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of global costs and potential profits sharing ratio |  |  | 50.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration And License Agreement [Member] | Takeda [Member] | Category Two Programs [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fund receivable for research and preclinical activities |  |  | $ 60,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research term under collaboration and license agreement |  |  | 4 years |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum targets for preclinical programs | Target |  |  | 6 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Option to reach maximum targets for preclinical programs |  |  |  |  |  |  |  |  |  |  |  |  |  | any one time |  |  |
Collaboration And License Agreement [Member] | Takeda [Member] | Minimum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration agreement, committed cash |  |  |  | $ 230,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration and Share Purchase Agreements [Member] | Takeda [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shares issued under equity agreement | shares |  |  | 1,096,892 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity investment aggregate purchase price |  |  | $ 60,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Purchase price per share | $ / shares |  |  | $ 54.70 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Proceeds from issuance of ordinary shares, net of offering costs |  |  | $ 60,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity investment agreement official closure month and year |  |  | 2018-04 |  |  |  |  |  |  |  |  |  |  |  |  |  |

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130533-203044 + Details
Name: | us-gaap_ContractWithCustomerAssetNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130533-203044 + Details
Name: | us-gaap_ContractWithCustomerAssetNetCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045 + Details
Name: | us-gaap_ContractWithCustomerLiabilityCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045 + Details
Name: | us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The cash inflow from the additional capital contribution to the entity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585 + Details
Name: | us-gaap_ProceedsFromIssuanceOfCommonStock
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. + References No definition available. + Details
Name: | us-gaap_SaleOfStockPricePerShare
Namespace Prefix: | us-gaap_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Per share or per unit amount of equity securities issued. + References No definition available. + Details
Name: | us-gaap_SharesIssuedPricePerShare
Namespace Prefix: | us-gaap_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of new stock issued during the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_StockIssuedDuringPeriodValueNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaboration agreement additional period after research term. + References No definition available. + Details
Name: | wve_CollaborationAgreementAdditionalPeriodAfterResearchTerm
Namespace Prefix: | wve_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaboration agreement commencement date. + References No definition available. + Details
Name: | wve_CollaborationAgreementCommencementDate
Namespace Prefix: | wve_
Data Type: | xbrli:dateItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaboration agreement committed cash. + References No definition available. + Details
Name: | wve_CollaborationAgreementCommittedCash
Namespace Prefix: | wve_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaboration agreement remaining research term. + References No definition available. + Details
Name: | wve_CollaborationAgreementRemainingResearchTerm
Namespace Prefix: | wve_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaboration agreement upfront payment. + References No definition available. + Details
Name: | wve_CollaborationAgreementUpfrontPayment
Namespace Prefix: | wve_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaboration and license agreement month and year. + References No definition available. + Details
Name: | wve_CollaborationAndLicenseAgreementMonthAndYear
Namespace Prefix: | wve_
Data Type: | xbrli:gYearMonthItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaboration and license agreement research term. + References No definition available. + Details
Name: | wve_CollaborationAndLicenseAgreementResearchTerm
Namespace Prefix: | wve_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative agreement research period. + References No definition available. + Details
Name: | wve_CollaborativeAgreementResearchPeriod
Namespace Prefix: | wve_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Counterparty nominations number of research programs. + References No definition available. + Details
Name: | wve_CounterpartyNominationsNumberOfResearchPrograms
Namespace Prefix: | wve_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity investment agreement official closure date month and year. + References No definition available. + Details
Name: | wve_EquityInvestmentAgreementOfficialClosureDateMonthAndYear
Namespace Prefix: | wve_
Data Type: | xbrli:gYearMonthItemType
Balance Type: | na
Period Type: | duration

X
- Definition Fund receivable for research and preclinical activities. + References No definition available. + Details
Name: | wve_FundReceivableForResearchAndPreclinicalActivities
Namespace Prefix: | wve_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Maximum targets for preclinical programs. + References No definition available. + Details
Name: | wve_MaximumTargetsForPreclinicalPrograms
Namespace Prefix: | wve_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Maximum termination notice period. + References No definition available. + Details
Name: | wve_MaximumTerminationNoticePeriod
Namespace Prefix: | wve_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Option to reach maximum targets for preclinical programs. + References No definition available. + Details
Name: | wve_OptionToReachMaximumTargetsForPreclinicalPrograms
Namespace Prefix: | wve_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of global costs and potential profits sharing ratio. + References No definition available. + Details
Name: | wve_PercentageOfGlobalCostsAndPotentialProfitsSharingRatio
Namespace Prefix: | wve_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Refundable collaborative arrangement allocable revenue. + References No definition available. + Details
Name: | wve_RefundableCollaborativeArrangementAllocableRevenue
Namespace Prefix: | wve_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Research term description. + References No definition available. + Details
Name: | wve_ResearchTermDescription
Namespace Prefix: | wve_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Up-front consideration received. + References No definition available. + Details
Name: | wve_UpFrontConsiderationReceived
Namespace Prefix: | wve_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=wve_PfizerIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=wve_TakedaPharmaceuticalCompanyLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=wve_ResearchLicenseAndOptionAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=wve_CollaborationAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=wve_CategoryOneProgramsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=wve_CategoryTwoProgramsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=wve_CollaborationAndSharePurchaseAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |